$73.87-2.14% · 3M
Moving avg
1W+1.66%
1M-0.89%
3M-0.48%
6M-41.68%
YTD-41.34%
1Y-51.74%
3Y-61.05%
5Y-63.93%
52-week range
$71.473% of range$160.48
Company health
Value4/6
Growth3/6
Profitability6/6
Health3/6
Dividend5/6
Bull vs bear
Strengths
- Reasonably valued at 12.8x earnings
- Analysts see 37% upside to a $102 target
- Strong 28% net margin
- High return on equity (6241%)
- Pays a 2.7% dividend
Risks
- Highly leveraged (debt is 2.8x equity)
Key statistics
Valuation
Market cap
$30.97B
Enterprise value
$39.67B
P/E ratio (TTM)
12.78x
P/S ratio (TTM)
3.40x
EV/EBITDA
9.84x
Per share & returns
EPS (TTM)
$6.26
Dividend yield
2.71%
Beta (1Y)
0.75
30-day change
-0.89%
Trading
Volume (24h)
1.88M
Previous close
$73.54
Shares outstanding
419.23M
About Zoetis Inc.
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NYSE
Symbol
ZTS
Zoetis Inc. is a large-cap healthcare company in the Drug Manufacturers - General industry. Its shares are listed on NYSE (United States) and trade under the ticker ZTS.
Frequently asked questions
What is Zoetis Inc.'s market cap?
Zoetis Inc. (ZTS) has a market capitalization of $30.97B.
What is Zoetis Inc.'s P/E ratio?
Zoetis Inc. trades at a price-to-earnings (P/E) ratio of 12.78.
What exchange does ZTS trade on?
ZTS trades on NYSE.
Appears in
Eli Lilly and CompanyLLY
$1,218.31-0.16%
$1.15T cap
Johnson & JohnsonJNJ
$261.30+0.17%
$629.71B cap
AbbVie Inc.ABBV
$250.30+0.62%
$442.23B cap
UnitedHealth Group IncorporatedUNH
$402.11-0.86%
$365.17B cap
Roche Holding AGSWX: ROP
CHF 362.30-0.88%
$355.30B cap
Merck & Co., Inc.MRK
$134.70+1.34%
$332.68B cap
Novartis AGSWX: NOVN
CHF 123.74-0.37%
$289.76B cap
AstraZeneca PLCLON: AZN
£117.08+0.05%
$245.27B cap